Featured News See All May 14, 2026 REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights May 14, 2026 REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 May 7, 2026 REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting Year All20262025202420232022202120202019201820172016201520142013201220112009 May 18, 2026 REGENXBIO to Participate in Upcoming Investor Conferences May 14, 2026 REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights May 14, 2026 REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 May 07, 2026 REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting May 06, 2026 REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy Mar 11, 2026 REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 Mar 05, 2026 REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
May 14, 2026 REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
May 07, 2026 REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting
May 06, 2026 REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy
Mar 11, 2026 REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
Mar 05, 2026 REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
